BiotechTube
Isofol Medical

Isofol Medical

Gothenburg, Sweden· Est.
isofolmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $42M

Overview

Isofol Medical is a clinical-stage biotech company developing arfolitixorin, an optimized folate designed to potentiate standard 5-FU-based chemotherapy in metastatic colorectal cancer (mCRC). The company is currently conducting a Phase Ib/II study and is publicly traded on Nasdaq Stockholm. With a focus on a high-mortality cancer where current folate therapies are suboptimal, Isofol seeks to address a significant unmet medical need and improve standard-of-care outcomes.

OncologyNeurology

Technology Platform

Development of arfolitixorin ([6R]-5,10-methylenetetrahydrofolate), a pre-activated, optimized folate co-factor designed to maximize the efficacy of 5-FU chemotherapy by bypassing the metabolic activation required by current standard folates.

Funding History

3
Total raised:$42M
Series B$25M
Series A$15M
Seed$2M

Opportunities

The primary opportunity is to replace leucovorin, a generic drug used globally for decades, as the standard folate component in 5-FU chemotherapy for metastatic colorectal cancer, addressing a large market with high unmet need.
A secondary, exploratory opportunity exists in expanding the use of arfolitixorin into neurological disorders like autism, potentially leveraging folate metabolism in a new therapeutic area.

Risk Factors

The major risk is clinical, as the drug candidate previously failed a Phase III trial and must now prove its value in a new study.
Financial risk is high due to dependence on capital markets for funding.
Commercial risk exists in displacing a low-cost, entrenched standard of care even if clinical success is achieved.

Competitive Landscape

In mCRC, arfolitixorin's direct competitor is generic leucovorin (and its various salts), which is cheap and deeply embedded in treatment protocols. It also competes with other modulators of 5-FU therapy and newer targeted/immunotherapies. Its potential advantage is being a superior, bio-optimized version of an essential co-therapy, rather than a completely new agent.

More companies in Sweden →